Education:
BS
University of Central Arkansas , 1990
MS
University of Central Arkansas , 1992
PhD
University of Arkansas for Medical Sciences, Little Rock , Arkansas , 2003
Research Interest :
My research interests include identification of novel markers of susceptibility to carcinogens in diet and the contribution of genetic variation in relationship to response to therapeutic agents. My collaborators and I have examined genetic variability in drug metabolizing enzymes, exposure to putative carcinogens in the diet and their combined role in the etiology of certain cancers. I am also interested how genetic variation in the enzymes that metabolize therapeutic agents relates to response to treatment and have reported that common genetic polymorphisms in SULT1A1 influences overall survival in breast cancer patients receiving tamoxifen therapy. Currently, this concept has been extended to the investigation of genetic polymorphisms in other therapeutic agents for breast cancer, including aromatase inhibitiors and pure antiestrogens. I am also interested in the role of genetic variability in the observed racial disparities in breast cancer incidence and mortality between Caucasian and African-American women.
Selected Publications:
Nowell S** , Massengill J, Williams S, Radominska-Pandya A, Tephly T, Cheng Z, Strassburg C, Tukey R, MacLeod, SL, Lang NP, Kadlubar FF. Glucuronidation of N -OH-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human microsomal UDP-glucuronosyltransferases: Identification of specific UGT1A family isoforms involved. Carcinogenesis 20(6): 1107-1114, 1999.
Nowell S** , Ambrosone CB, Ozawa S, MacLeod SL, Mrackova G, Williams S, Plaxco J, Kadlubar FF, Lang NP. Relatioship of phenol sulfotransferase (SULT1A1) genotype to sulfotransferase activity phenotype in platelet cytosol. Pharmacogenetics . 10(9): 789-797, 2000.
Nowell S** , Sweeney C, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention . 11(4): 377-383, 2002.
Nowell S**, Sweeney C, Winters M, Stone A, Fares MY, Lang NP, Kadlubar FF, Ambrosone CB. Relationship of sulfotransferase 1A1 (SULT1A1) genotype to survival of breast cancer patients receiving tamoxifen therapy. Journal of the National Cancer Institute 94(1): 1635-1640, 2002.
Nowell S** , Ratnasinghe DL, Ambrosone CB, Williams S, Teague-Ross T, Trimble L, Runnels G, Carrol A, Green B, Stone A, Greene G, Kadlubar FF, Lang NP. Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiology, Biomarkers and Prevention , 13(2):270-276, 2004.
Nowell S**, Green B, Tang YM, Wiese F, Kadlubar FF. Analysis of the distribution of SULT1A2 protein in human tissue using a specific SULT1A2 antibody. Molecular Pharmacology , Nov.4 (epub) 2004.
Nowell S** , Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Research and Treatment , 91(3):249-58, 2005.
Ning B, Nowell S** , Sweeney C, Ambrosone CB, Williams S, Miao X, Liang G, Lin D, Stone A, Ratnasinghe DL, Manjanatha M, Lang NP, Kadlubar FF. Common genetic polymorphisms in the 5'-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity. Pharmacogenetics , 15(7):465-473, 2005 |
